PROJ-SUN_1170x120_6-24-20

Rajiv De Silva

CEO succession at Endo

CEO succession at Endo

DUBLIN, Ireland — Endo International plc has appointed Paul Campanelli, as president and chief executive officer, succeeding Rajiv De Silva, who is stepping down. Endo said Campanelli, who was president of its generic drugs and OTC business, takes the helm as president and CEO effective immediately. With the move, he will take De Silva’s spot

Endo tabs Ciaffoni as U.S branded Rx president

Endo tabs Ciaffoni as U.S branded Rx president

DUBLIN, Ireland — Joseph Ciaffoni has been named president of U.S. branded pharmaceuticals at Endo International plc. Endo said Ciaffoni is slated to start in the new post on Aug. 15. He joins the company from Biogen, where he was senior vice president of the global specialty medicines group. “I am thrilled to be joining

Endo granted extended U.S. rights for Voltaren Gel

Endo granted extended U.S. rights for Voltaren Gel

DUBLIN, Ireland — Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID). Endo said Monday that it also was granted extended U.S. rights for the product’s authorized generic, should the company choose to launch it commercially in the future. Through an indirect

Endo cleared to market Belbuca dissolving film painkiller

Endo cleared to market Belbuca dissolving film painkiller

DUBLIN, Ireland, and RALEIGH, N.C. — Endo Pharmaceuticals Inc. and BioDelivery Sciences International Inc. have gained approval from the Food and Drug Administration for Belbuca buccal film (buprenorphine), an opioid treatment for chronic pain. The companies said Belbuca is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner

Endo wraps up Par Pharma acquisition

Endo wraps up Par Pharma acquisition

DUBLIN, Ireland — Endo International plc has completed its $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. from leading global private investment firm TPG. Endo said Monday that with the closing of the deal, announced in May, its U.S. Generics segment that includes Par Pharmaceutical and Qualitest will be named Par Pharmaceutical, an Endo International